Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01118728 · ClinicalTrials.gov registry record · Phase 2
Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis
A Phase 2 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 2
- Development phase
- 223
- Enrollment target
NCT01118728 is a Phase 2 study that was terminated before completion, run by Sanofi. The registered enrollment target is 223 participants.
The verdict
NCT01118728, a Phase 2 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 223 participants
- Enrollment target
Study Summary
Primary Objective: * To assess the long term safety of Sarilumab (SAR153191/REGN88) in participants with ankylosing spondylitis (AS) Secondary Objective: * To assess the long term efficacy of Sarilumab (SAR153191/REGN88) in participants with AS
Interventions
- DRUG Sarilumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 223 participants |
| Start Date | 2010-06 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01118728
The ClinicalTrials.gov registry entry for NCT01118728 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 223 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sarilumab is the first listed.
NCT01118728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01118728 about?
NCT01118728 is a clinical study titled "Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis". Primary Objective: * To assess the long term safety of Sarilumab (SAR153191/REGN88) in participants with ankylosing spondylitis (AS) Secondary Objective: * To assess the long term efficacy of Sarilumab (SAR153191/REGN88) in participants with AS
What is the current status of trial NCT01118728?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 223 participants. The study started on 2010-06. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01118728?
The interventions under investigation include: Sarilumab (DRUG).
Who is sponsoring clinical trial NCT01118728?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.